Skip to main content

Dermatology vs Immunology — Deal Terms Comparison

Dermatology Median Upfront
$393M
Total: $2.1B
Immunology Median Upfront
$480M
Total: $2.5B
Dermatology Royalties
6.5%-13.1%
Tiered to 17.1%
Immunology Royalties
13.2%-22.1%
Tiered to 26.1%

Market Analysis

Dermatology and Immunology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 dermatology deals carry a median total deal value of $2.1B with $393M upfront, compared to $2.5B total value and $480M upfront for immunology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do dermatology and immunology deal terms compare?
Dermatology Phase 2 deals average $2.1B total value ($393M upfront), while Immunology deals average $2.5B ($480M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating